Abstract

Activated factor XII (FXIIa) is selectively inhibited by corn Hageman factor inhibitor (CHFI) among other plasma proteases. CHFI is considered a canonical serine protease inhibitor that interacts with FXIIa through its protease-binding loop. Here we examined whether the protease-binding loop alone is sufficient for the selective inhibition of serine proteases or whether other regions of a canonical inhibitor are involved. Six CHFI mutants lacking different N- and C-terminal portions were generated. CHFI-234, which lacks the first and fifth disulfide bonds and 11 and 19 amino acid residues at the N and C termini, respectively, exhibited no significant changes in FXIIa inhibition (Ki = 3.2 ± 0.4 nm). CHFI-123, which lacks 34 amino acid residues at the C terminus and the fourth and fifth disulfide bridges, inhibited FXIIa with a Ki of 116 ± 16 nm. To exclude interactions outside the FXIIa active site, a synthetic cyclic peptide was tested. The peptide contained residues 20-45 (Protein Data Bank code 1BEA), and a C29D substitution was included to avoid unwanted disulfide bond formation between unpaired cysteines. Surprisingly, the isolated protease-binding loop failed to inhibit FXIIa but retained partial inhibition of trypsin (Ki = 11.7 ± 1.2 μm) and activated factor XI (Ki = 94 ± 11 μm). Full-length CHFI inhibited trypsin with a Ki of 1.3 ± 0.2 nm and activated factor XI with a Ki of 5.4 ± 0.2 μm. Our results suggest that the protease-binding loop is not sufficient for the interaction between FXIIa and CHFI; other regions of the inhibitor also contribute to specific inhibition.

Highlights

  • Canonical inhibitors interact with cognate proteases through a protease-binding loop

  • Nonloop regions of corn Hageman factor inhibitor (CHFI) are required for specific inhibition of FXIIa

  • CHFI is considered a canonical serine protease inhibitor that interacts with FXIIa through its protease-binding loop

Read more

Summary

Conclusion

Nonloop regions of CHFI are required for specific inhibition of FXIIa. Significance: CHFI is the first canonical inhibitor whose protease-binding loop is not sufficient for cognate enzyme inhibition. Our results suggest that the protease-binding loop is not sufficient for the interaction between FXIIa and CHFI; other regions of the inhibitor contribute to specific inhibition. Studies of serine protease-canonical inhibitor interactions suggested that the protease-binding loop is a minimal and sufficient base for inhibitory activity. Based on the available data related to small peptide serine protease inhibitors, we propose that the isolated protease-binding loop of CHFI is a promising primary structure for the development of new FXIIa inhibitors. The cyclic peptide CHFI-2, which represents the CHFI protease-binding loop bridged with one disulfide bond, is unable to inhibit FXIIa but retains its inhibitory activity against bovine pancreatic trypsin and activated coagulation factor XI (FXIa). We report the first simple protocol for soluble expression of CHFI in Escherichia coli

EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call